8. Further Characterization of U2 snRNP Mediated Restriction of AAV Vector Transduction
Publication
, Conference
Schreiber, CA; Izumiya, Y; Asokan, A; Ikeda, Y
Published in: Molecular Therapy
May 2016
Duke Scholars
Published In
Molecular Therapy
DOI
ISSN
1525-0016
Publication Date
May 2016
Volume
24
Start / End Page
S4 / S5
Publisher
Elsevier BV
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics
- 11 Medical and Health Sciences
- 10 Technology
- 06 Biological Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Schreiber, C. A., Izumiya, Y., Asokan, A., & Ikeda, Y. (2016). 8. Further Characterization of U2 snRNP Mediated Restriction of AAV Vector Transduction. In Molecular Therapy (Vol. 24, pp. S4–S5). Elsevier BV. https://doi.org/10.1016/s1525-0016(16)32817-9
Schreiber, Claire A., Yoshihiro Izumiya, Aravind Asokan, and Yasuhiro Ikeda. “8. Further Characterization of U2 snRNP Mediated Restriction of AAV Vector Transduction.” In Molecular Therapy, 24:S4–5. Elsevier BV, 2016. https://doi.org/10.1016/s1525-0016(16)32817-9.
Schreiber CA, Izumiya Y, Asokan A, Ikeda Y. 8. Further Characterization of U2 snRNP Mediated Restriction of AAV Vector Transduction. In: Molecular Therapy. Elsevier BV; 2016. p. S4–5.
Schreiber, Claire A., et al. “8. Further Characterization of U2 snRNP Mediated Restriction of AAV Vector Transduction.” Molecular Therapy, vol. 24, Elsevier BV, 2016, pp. S4–5. Crossref, doi:10.1016/s1525-0016(16)32817-9.
Schreiber CA, Izumiya Y, Asokan A, Ikeda Y. 8. Further Characterization of U2 snRNP Mediated Restriction of AAV Vector Transduction. Molecular Therapy. Elsevier BV; 2016. p. S4–S5.
Published In
Molecular Therapy
DOI
ISSN
1525-0016
Publication Date
May 2016
Volume
24
Start / End Page
S4 / S5
Publisher
Elsevier BV
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics
- 11 Medical and Health Sciences
- 10 Technology
- 06 Biological Sciences